In particular, given the association of HDAC1 and HDAC6 with the progression of AML and CLL – two hematologic cancers for which venetoclax has already received FDA approval – we elected to focus on achieving HDAC1 and HDAC6 selectivity in our dual BCL‐2/HDAC inhibitors. Here, HDAC1 is linked to hematopoietic and lymphoid cell neoplasm.